Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05504057
Recruiting Observational

Antihistamines, Amantadine and Evolution of COVID-19

NCT05504057 · tracked via the Priya Life Science Spain tracker
Sponsor
Consorci Sanitari de Terrassa
Phase
Observational
Started
2020-03-01
Last updated
2026-04-03

Condition(s) studied

COVID-19

Investigational drug(s) / intervention(s)

AntihistamineAmantadine →

Antihistamine: Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

Amantadine: Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Study summary

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine - Exclusion Criteria: None \-

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Hospital de Terrassa Terrassa Barcelona Recruiting
Hospital of Terrassa Terrassa Barcelona Recruiting

More Consorci Sanitari de Terrassa trials in Spain

Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy Active, not recruiting
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection Recruiting
Treatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) Starting soon
2024 NewAnescat Register Recruiting
Emotional Intelligence Intervention to Improve Mental Well-Being of Adolescents With Emotional Distress (BEAM) Active, not recruiting

Other trials for the same condition

Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19 Active, not recruiting
Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years Starting soon
Prevalence of Long COVID-19 in the Canary Islands Recruiting
Profile of COVID-19 Patients Related to Fatigue Active, not recruiting
International Survey of Acute Coronavirus Syndromes-COVID-19 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05504057 on ClinicalTrials.gov ↗ ← All trials in Spain